All In Biotech

Drug Trial Radar · NCT01970371

A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)

A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)

Last checked: Nov 20, 2026Latest source record: Oct 16, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

69

Actual

Start

Sep 16, 2014

Primary completion

Aug 18, 2016

Study completion Sep 15, 2016

Sponsor

Lead sponsor
Achaogen, Inc.Industry
Sponsor type
Industry
Collaborators
Department of Health and Human Services
First posted
Oct 28, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in the treatment of patients with bloodstream infection (BSI), hospital acquired bacterial pneumonia (HABP), or ventilator-associated bacterial pneumonia (VABP) due to CRE. An additional cohort of patients with BSI, HABP, VABP, complicated urinary tract infection (cUTI), or acute pyelonephritis (AP) due to CRE, not eligible for inclusion in the other cohort, were enrolled into a single arm (Cohort 2) and treated with plazomicin-based therapy. Therapeutic drug management (TDM) was used to help ensure that plazomicin exposures lie within an acceptable range of the target mean steady-state area under the curve (AUC).

Conditions

  • Bloodstream Infections (BSI) Due to CRE
  • Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
  • Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE
  • Complicated Urinary Tract Infection (cUTI) Due to CRE
  • Acute Pyelonephritis (AP) Due to CRE

Interventions

  • plazomicinDrug

  • colistinDrug

  • meropenemDrug

  • tigecyclineDrug

  • antibiotic of Investigator's choiceDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With All Cause Mortality (ACM) at Day 28 or Significant Disease-Related Complication (SDRC) in the Microbiological Modified Intent to Treat (mMITT) Population in Cohort 1Time frame: Up to Day 28 for ACM, up to 7 Days for SDRCs in all patients, on or after Day 5 for BSI patients only.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.